Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Roche,Atezolizumab,"Urothelial carcinoma, locally advanced or metastatic, 2nd line",Atezolizumab,Recommended for decline,Hospital,Oncology Agents and Immunosuppressants
